Patents by Inventor Xinxing Tang

Xinxing Tang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heteroaromatic macrocyclic ether chemotherapeutic agents
    Patent number: 11667649
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: November 11, 2021
    Date of Patent: June 6, 2023
    Assignee: Nuvalent, Inc.
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS
    Publication number: 20230107663
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The disclosure further relates to methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof.
    Type: Application
    Filed: June 7, 2022
    Publication date: April 6, 2023
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS
    Publication number: 20230076627
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
    Type: Application
    Filed: June 7, 2022
    Publication date: March 9, 2023
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • Heteroaromatic macrocyclic ether chemotherapeutic agents
    Patent number: 11542278
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds of Formula (I): pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The disclosure further relates to methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: January 3, 2023
    Assignee: Nuvalent, Inc.
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS
    Publication number: 20220340586
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof Also disclosed are methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
    Type: Application
    Filed: November 11, 2021
    Publication date: October 27, 2022
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS
    Publication number: 20220098212
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof Also disclosed are methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
    Type: Application
    Filed: November 11, 2021
    Publication date: March 31, 2022
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • Preparation of hydroxy-benzylbenzene derivatives
    Patent number: 10093616
    Abstract: Methods for preparing intermediates of SGLT2 inhibitors are provided, including crystalline forms and methods of crystallizing intermediates.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: October 9, 2018
    Assignee: THERACOS SUB, LLC
    Inventors: Jacques Roberge, Carine Vaxelaire, Baohu Liu, Ge Xu, Jian Zhang, Xinxing Tang, Baihua Xu
  • PREPARATION OF HYDROXY-BENZYLBENZENE DERIVATIVES
    Publication number: 20160355471
    Abstract: Methods for preparing intermediates of SGLT2 inhibitors are provided, including crystalline forms and methods of crystallizing intermediates.
    Type: Application
    Filed: August 16, 2016
    Publication date: December 8, 2016
    Inventors: Jacques ROBERGE, Carine VAXELAIRE, Baohu LIU, Ge XU, Jian ZHANG, Xinxing TANG, Baihua XU
  • Preparation of hydroxy-benzylbenzene derivatives
    Patent number: 9464043
    Abstract: Methods for preparing intermediates of SGLT2 inhibitors are provided, including crystalline forms and methods of crystallizing intermediates.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: October 11, 2016
    Assignee: THERACOS SUB, LLC
    Inventors: Jacques Roberge, Carine Vaxelaire, Baohu Liu, Ge Xu, Jian Zhang, Xinxing Tang, Baihua Xu
  • PREPARATION OF HYDROXY-BENZYLBENZENE DERIVATIVES
    Publication number: 20150210634
    Abstract: Methods for preparing intermediates of SGLT2 inhibitors are provided, including crystalline forms and methods of crystallizing intermediates.
    Type: Application
    Filed: October 10, 2014
    Publication date: July 30, 2015
    Inventors: Jacques Roberge, Carine Vaxelaire, Baohu Liu, Ge Xu, Jian Zhang, Xinxing Tang, Baihua Xu
  • Deuterated benzylbenzene derivatives and methods of use
    Patent number: 9061060
    Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by SGLT inhibition.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: June 23, 2015
    Assignee: Theracos Inc.
    Inventors: Brian Seed, Binhua Lv, Jacques Y. Roberge, Yuanwei Chen, Kun Peng, Jiajia Dong, Baihua Xu, Jiyan Du, Lili Zhang, Xinxing Tang, Ge Xu, Yan Feng, Min Xu
  • DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE
    Publication number: 20100063141
    Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by SGLT inhibition.
    Type: Application
    Filed: July 15, 2009
    Publication date: March 11, 2010
    Applicant: Theracos, Inc.
    Inventors: Brian Seed, Binhua LV, Jacques Y. Roberge, Yuanwei Chen, Kun Peng, Jiajia Dong, Baihua Xu, Jiyan Du, Lili Zhang, Xinxing Tang, Ge Xu, Yan Feng, Min Xu